Index -
P/E 237.66
EPS (ttm) 0.72
Insider Own 7.02%
Shs Outstand 55.77M
Perf Week 4.33%
Market Cap 9.55B
Forward P/E 83.38
EPS next Y 2.05
Insider Trans -0.74%
Shs Float 51.85M
Perf Month -13.51%
Income 41.58M
PEG 13.23
EPS next Q 0.30
Inst Own 105.06%
Short Float 9.20%
Perf Quarter -8.43%
Sales 638.76M
P/S 14.95
EPS this Y -16.68%
Inst Trans 1.47%
Short Ratio 9.16
Perf Half Y 17.34%
Book/sh 35.35
P/B 4.85
EPS next Y 40.87%
ROA 1.55%
Short Interest 4.77M
Perf Year 3.12%
Cash/sh 13.47
P/C 12.71
EPS next 5Y 17.96%
ROE 2.14%
52W Range 110.45 - 211.13
Perf YTD -4.74%
Dividend Est. -
P/FCF 127.48
EPS past 5Y 15.08%
ROI 1.59%
52W High -18.87%
Beta 1.04
Dividend TTM -
Quick Ratio 5.75
Sales past 5Y 31.42%
Gross Margin 44.49%
52W Low 55.07%
ATR (14) 6.62
Dividend Ex-Date -
Current Ratio 7.02
EPS Y/Y TTM -77.69%
Oper. Margin 9.71%
RSI (14) 45.97
Volatility 4.16% 3.32%
Employees 1783
Debt/Eq 0.36
Sales Y/Y TTM -20.31%
Profit Margin 6.51%
Recom 1.54
Target Price 210.98
Option/Short Yes / Yes
LT Debt/Eq 0.32
EPS Q/Q -153.51%
Payout 0.00%
Rel Volume 1.78
Prev Close 157.48
Sales Surprise -8.57%
EPS Surprise 1.29%
Sales Q/Q -16.61%
Earnings May 01 BMO
Avg Volume 521.10K
Price 171.28
SMA20 -1.14%
SMA50 -8.67%
SMA200 0.67%
Trades
Volume 928,604
Change 8.76%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-04-23 Downgrade
The Benchmark Company
Buy → Hold
Jul-20-23 Initiated
Wells Fargo
Overweight
$185
Jul-05-23 Resumed
JP Morgan
Overweight
$220
Mar-28-23 Initiated
The Benchmark Company
Buy
$230
Dec-14-22 Initiated
Deutsche Bank
Hold
$180
Dec-07-22 Initiated
RBC Capital Mkts
Sector Perform
$190
Jul-20-22 Initiated
UBS
Buy
$213
Oct-14-21 Initiated
Exane BNP Paribas
Outperform
$330
Nov-10-20 Initiated
KeyBanc Capital Markets
Overweight
$241
Aug-24-20 Reiterated
H.C. Wainwright
Buy
$151 → $168
Jun-30-20 Reiterated
H.C. Wainwright
Buy
$143 → $151
May-07-20 Reiterated
H.C. Wainwright
Buy
$100 → $143
Mar-23-20 Reiterated
H.C. Wainwright
Buy
$110 → $100
Nov-15-19 Initiated
Stifel
Buy
Nov-01-19 Upgrade
First Analysis Sec
Outperform → Strong Buy
$107 → $110
Oct-15-19 Initiated
SVB Leerink
Outperform
$100
Aug-28-19 Reiterated
First Analysis Sec
Outperform
$95 → $107
Aug-23-19 Resumed
Stephens
Overweight
Jul-22-19 Upgrade
H.C. Wainwright
Neutral → Buy
$110
Dec-17-18 Upgrade
CL King
Neutral → Buy
Show Previous Ratings
Today 11:43AM
Apr-17-24 07:30AM
Apr-12-24 10:07AM
09:49AM
Mar-19-24 07:30AM
01:18AM
Loading…
Mar-12-24 01:18AM
Feb-27-24 02:02AM
Feb-24-24 12:03AM
Feb-22-24 11:24AM
10:39AM
Feb-21-24 08:45AM
08:12AM
07:51AM
(Associated Press Finance)
07:30AM
Feb-07-24 07:30AM
12:10PM
Loading…
Jan-31-24 12:10PM
Jan-29-24 05:09AM
Dec-19-23 07:30AM
Dec-18-23 04:49AM
Dec-07-23 07:30AM
Nov-30-23 11:31AM
Nov-15-23 07:15AM
Nov-14-23 02:01PM
07:30AM
Nov-07-23 07:30AM
Nov-02-23 07:30AM
Nov-01-23 12:10PM
11:46AM
12:04AM
(Thomson Reuters StreetEvents)
Oct-31-23 09:41AM
09:12AM
Loading…
09:12AM
08:50AM
07:41AM
(Associated Press Finance)
07:30AM
Oct-25-23 10:01AM
Oct-24-23 10:00AM
Oct-17-23 11:44AM
07:30AM
Oct-02-23 07:30AM
Sep-27-23 06:51AM
Sep-26-23 12:41PM
(American City Business Journals)
07:30AM
Sep-14-23 10:10AM
Sep-12-23 07:30AM
Sep-06-23 03:06AM
Sep-01-23 12:19PM
11:31AM
07:30AM
Aug-21-23 06:53AM
Aug-17-23 08:00AM
Aug-10-23 09:39AM
Aug-09-23 06:10AM
Aug-03-23 11:19AM
Aug-02-23 08:55AM
07:49AM
07:30AM
Jul-31-23 09:08AM
Jul-26-23 10:02AM
Jul-25-23 11:40AM
Jul-20-23 10:01AM
Jul-19-23 07:30AM
Jul-10-23 08:34AM
Jun-30-23 10:54AM
Jun-21-23 08:00PM
Jun-07-23 11:30AM
Jun-02-23 11:31AM
Jun-01-23 11:31AM
May-31-23 07:30AM
May-30-23 12:09PM
May-09-23 05:52PM
May-03-23 01:20PM
May-02-23 11:36PM
(Thomson Reuters StreetEvents)
08:55AM
07:52AM
07:30AM
07:02AM
May-01-23 07:43AM
Apr-26-23 08:00PM
10:02AM
Apr-25-23 02:07PM
10:01AM
Apr-18-23 07:30AM
Apr-11-23 02:41PM
Mar-24-23 11:30AM
Mar-14-23 07:30AM
Feb-23-23 06:28PM
01:41PM
05:54AM
Feb-22-23 08:55AM
07:30AM
Feb-20-23 06:34AM
Feb-09-23 07:30AM
Feb-08-23 07:30AM
Jan-21-23 09:51AM
Jan-19-23 03:10AM
Jan-13-23 08:30AM
Jan-12-23 05:00PM
11:40AM
Jan-03-23 07:30AM
Dec-21-22 10:56AM
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
KURIYEL RALF Senior VP, R&D Mar 11 '24 Option Exercise 86.10 1,271 109,433 27,777 Mar 12 08:24 PM KURIYEL RALF Senior VP, R&D Mar 11 '24 Sale 193.73 3,517 681,348 24,260 Mar 12 08:24 PM Hunt Anthony Chief Executive Officer Mar 08 '24 Option Exercise 16.55 1 17 201,956 Mar 11 07:43 PM Hunt Anthony Chief Executive Officer Mar 08 '24 Sale 197.44 16,707 3,298,632 185,249 Mar 11 07:43 PM DAWES KAREN A Director Feb 27 '24 Option Exercise 42.07 4,626 194,616 88,367 Feb 28 09:56 PM DAWES KAREN A Director Feb 27 '24 Sale 193.35 1,000 193,350 87,367 Feb 28 09:56 PM Bylund James Chief Operating Officer Feb 23 '24 Option Exercise 94.33 940 88,670 18,508 Feb 26 08:38 PM Bylund James Chief Operating Officer Feb 23 '24 Sale 198.08 4,373 866,204 14,135 Feb 26 08:38 PM Gebski Christine See Remarks Nov 10 '23 Sale 147.13 3,788 557,328 28,787 Nov 13 05:10 PM DAWES KAREN A Director Aug 29 '23 Option Exercise 18.12 7,392 133,943 84,591 Aug 30 04:06 PM DAWES KAREN A Director Aug 29 '23 Sale 171.38 850 145,673 83,741 Aug 30 04:06 PM Madaus Martin D Director May 08 '23 Buy 156.18 500 78,090 1,611 May 08 09:15 PM Madaus Martin D Director May 05 '23 Buy 159.19 500 79,595 1,111 May 08 09:15 PM Madaus Martin D Director May 04 '23 Buy 161.15 500 80,575 611 May 08 09:15 PM
Index RUT
P/E -
EPS (ttm) -3.97
Insider Own 5.92%
Shs Outstand 94.67M
Perf Week 14.30%
Market Cap 86.40M
Forward P/E 181.90
EPS next Y 0.01
Insider Trans -0.18%
Shs Float 89.37M
Perf Month -12.55%
Income -331.94M
PEG -
EPS next Q -0.03
Inst Own 49.33%
Short Float 11.61%
Perf Quarter 7.56%
Sales 152.07M
P/S 0.57
EPS this Y -121.82%
Inst Trans 11.54%
Short Ratio 11.40
Perf Half Y -60.11%
Book/sh 1.46
P/B 0.62
EPS next Y 104.17%
ROA -94.80%
Short Interest 10.38M
Perf Year -85.26%
Cash/sh 0.77
P/C 1.18
EPS next 5Y 25.00%
ROE -182.52%
52W Range 0.75 - 8.01
Perf YTD -15.00%
Dividend Est. -
P/FCF 1.76
EPS past 5Y -
ROI -186.50%
52W High -88.65%
Beta 1.01
Dividend TTM -
Quick Ratio 1.43
Sales past 5Y -7.51%
Gross Margin 64.04%
52W Low 21.11%
ATR (14) 0.06
Dividend Ex-Date -
Current Ratio 1.83
EPS Y/Y TTM -272.27%
Oper. Margin 10.79%
RSI (14) 52.56
Volatility 7.96% 6.45%
Employees 53
Debt/Eq 0.30
Sales Y/Y TTM -2.66%
Profit Margin -218.28%
Recom 1.00
Target Price 3.00
Option/Short Yes / Yes
LT Debt/Eq 0.29
EPS Q/Q -145.92%
Payout -
Rel Volume 1.21
Prev Close 0.87
Sales Surprise -3.39%
EPS Surprise -
Sales Q/Q -34.49%
Earnings Mar 11 AMC
Avg Volume 909.99K
Price 0.91
SMA20 1.45%
SMA50 0.22%
SMA200 -54.79%
Trades
Volume 1,100,433
Change 5.11%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-07-22 Initiated
Lake Street
Buy
$7
Nov-30-18 Downgrade
Mizuho
Buy → Neutral
Apr-03-24 08:00AM
Apr-01-24 09:00AM
Mar-12-24 11:11AM
08:31AM
05:49AM
(Thomson Reuters StreetEvents)
04:26PM
Loading…
Mar-11-24 04:26PM
(Associated Press Finance)
04:01PM
Mar-04-24 05:07PM
Feb-29-24 04:05PM
Feb-28-24 10:15AM
Feb-26-24 07:57PM
Feb-23-24 11:30AM
05:45AM
Feb-22-24 12:35PM
Feb-19-24 12:39PM
12:41PM
Loading…
Feb-16-24 12:41PM
11:28AM
Feb-13-24 05:45AM
Feb-12-24 10:30AM
Feb-09-24 02:51PM
Feb-05-24 03:56PM
10:24AM
10:08AM
Feb-02-24 12:32PM
12:19PM
Jan-29-24 12:30PM
Jan-26-24 09:15AM
Jan-24-24 06:54PM
10:15AM
Jan-22-24 03:42PM
09:36AM
Loading…
Jan-19-24 09:36AM
Jan-17-24 10:15AM
09:35AM
Jan-15-24 03:29PM
Jan-10-24 10:45AM
Jan-08-24 12:14PM
Jan-05-24 06:56PM
Jan-04-24 09:46AM
Jan-03-24 08:59AM
Dec-25-23 02:06PM
Nov-14-23 08:00AM
Nov-10-23 01:11PM
Nov-09-23 08:49AM
(Thomson Reuters StreetEvents) -43.19%
Nov-08-23 06:46PM
04:30PM
(Associated Press Finance)
04:01PM
Nov-02-23 12:06PM
Oct-06-23 04:30PM
Sep-22-23 08:38AM
Sep-14-23 01:12PM
Aug-28-23 06:30PM
Aug-25-23 04:05PM
Aug-23-23 08:48AM
Aug-08-23 04:45PM
09:15AM
Aug-06-23 08:05AM
07:14AM
Aug-03-23 04:29PM
(Associated Press Finance)
04:04PM
Jul-31-23 07:27PM
Jul-27-23 04:01PM
Jul-24-23 08:30AM
Jul-19-23 07:38AM
Jul-07-23 09:16AM
Jun-26-23 07:00AM
Jun-16-23 06:30AM
May-26-23 12:06PM
May-10-23 06:12AM
01:34AM
(Thomson Reuters StreetEvents)
May-09-23 07:28AM
07:15AM
06:02AM
May-05-23 08:00AM
May-04-23 10:54AM
06:10AM
Apr-27-23 09:00AM
Apr-25-23 01:03PM
06:00AM
Apr-24-23 09:00AM
09:00AM
Apr-17-23 06:43AM
Apr-10-23 09:00AM
Apr-07-23 04:00PM
Mar-29-23 10:13AM
Mar-27-23 09:00AM
Mar-14-23 09:00AM
Mar-10-23 02:37AM
Mar-09-23 12:19PM
(Thomson Reuters StreetEvents) +11.74%
Mar-08-23 11:43PM
(Thomson Reuters StreetEvents)
04:01PM
Mar-06-23 09:00AM
06:00AM
Mar-03-23 09:00AM
Mar-02-23 08:34AM
Mar-01-23 12:41PM
Feb-23-23 07:14AM
Feb-21-23 07:00AM
Feb-20-23 09:00AM
Feb-16-23 08:00AM
Feb-14-23 09:30AM
Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Tyree James L Director Mar 14 '24 Sale 1.12 10,251 11,463 188,251 Mar 15 08:01 PM Schlessinger Sam SVP, General Counsel Feb 21 '24 Option Exercise 0.00 17,151 0 109,384 Feb 23 05:32 PM Patel Ajay SVP and CFO Feb 21 '24 Option Exercise 0.00 17,151 0 141,760 Feb 23 05:30 PM Schwichtenberg Paul SVP, CCO Feb 21 '24 Option Exercise 0.00 17,151 0 112,430 Feb 23 05:31 PM Schlessinger Sam SVP, General Counsel Feb 11 '24 Option Exercise 0.00 18,939 0 98,785 Feb 13 07:02 PM Patel Ajay SVP and CFO Feb 11 '24 Option Exercise 0.00 47,348 0 140,991 Feb 13 07:00 PM Schwichtenberg Paul See Remarks Feb 11 '24 Option Exercise 0.00 47,348 0 111,661 Feb 13 07:01 PM Schlessinger Sam SVP, General Counsel Oct 01 '23 Option Exercise 0.00 19,404 0 88,442 Oct 03 07:27 PM Peisert Daniel A. President & CEO Sep 12 '23 Sale 2.97 31,121 92,432 324,939 Sep 13 08:15 PM Peisert Daniel A. President & CEO Sep 11 '23 Sale 3.04 127,281 386,972 356,060 Sep 13 08:15 PM Schwichtenberg Paul SVP and CFO Sep 11 '23 Sale 3.07 104,980 322,593 64,313 Sep 13 08:16 PM Patel Ajay SVP and CAO Sep 11 '23 Sale 3.04 64,313 195,794 93,643 Sep 13 08:17 PM Schlessinger Sam SVP, General Counsel Sep 11 '23 Sale 3.04 45,236 137,441 69,038 Sep 13 08:18 PM MCKEE WILLIAM Director Aug 14 '23 Sale 3.14 22,000 69,045 238,780 Aug 15 06:00 PM Schlessinger Sam SVP, General Counsel Aug 05 '23 Option Exercise 0.00 7,135 0 117,434 Aug 08 07:00 PM Mason Heather L Director May 19 '23 Sale 7.30 89,286 652,011 187,650 May 22 08:00 PM Patel Ajay SVP and CAO May 12 '23 Option Exercise 0.00 238,017 0 314,819 May 15 08:58 PM Schlessinger Sam SVP, General Counsel May 12 '23 Option Exercise 0.00 238,017 0 267,162 May 15 08:58 PM Peisert Daniel A. President and CEO May 12 '23 Option Exercise 0.00 552,067 0 797,066 May 15 08:57 PM Schwichtenberg Paul SVP and CFO May 12 '23 Option Exercise 0.00 238,017 0 326,156 May 15 08:58 PM Tyree James L Director May 05 '23 Sale 6.00 43,143 258,767 167,308 May 05 09:10 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite